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Trauma/hemorrhagic shock are associated with multiple organ dysfunction syndrome 
(MODS). Resolvin D1 (RvD1) is reduced in patients with trauma/MODS and 
administration of synthetic RvD1 reduces the organ injury/dysfunction in rats. These 
RvD1 beneficial effects are due to reduction of NF-κB activation, formation of 













Objectives: To evaluate the potential changes in the plasma levels of resolvin D1 
(RvD1) in patients with trauma and hemorrhage. Having found that trauma results in a 
profound reduction in plasma RvD1 in patients, we have then investigated the effects 
of RvD1 on the organ injury and dysfunction associated with hemorrhagic shock (HS) 
in the rat. 
Summary Background Data: HS is a common cause of death in trauma due to 
excessive systemic inflammation and multiple organ failure. RvD1 is a member of the 
resolvin family of pro-resolution mediators.   
Methods:  Blood samples were drawn from critically injured patients (n=27, ACITII-
prospective observational cohort study) within two hours of injury for targeted liquid 
chromatography tandem mass spectrometry. HS rats (removal of blood to reduce 
arterial pressure to 30±2 mmHg, 90 minutes, followed by resuscitation) were treated 
with RvD1 (0.3 or 1 µg/kg i.v.) or vehicle (n=7). Parameters of organ injury and 
dysfunction were determined.  
Results: Plasma levels of RvD1 (mg/dl) were reduced in patients with trauma+HS 
(0.17±0.08) when compared to healthy volunteers (0.76±0.25) and trauma patients 
(0.62±0.20). In rats with HS, RvD1 attenuated the kidney dysfunction, liver injury, and 
tissue ischemia. RvD1 also reduced activation of the NF-κB pathway and reduced the 
expression of pro-inflammatory proteins such as iNOS, TNF-α, IL-1β and IL-6.  
Conclusions: Plasma RvD1 is reduced in patients with trauma-HS. In rats with HS, 
administration of synthetic RvD1 on resuscitation attenuated the multiple organ failure 
associated with HS by a mechanism that involves inhibition of the activation of NF-κB.  
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Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, 
creatine kinase; iNOS, inducible nitric oxide synthase; HS, hemorrhagic shock; IL-6, 
interleukin 6; MAP, mean arterial pressure; MODS, multiple organ dysfunction 



















Despite improvements in trauma care, the morbidity and mortality associated with 
trauma remains very high. Approximately 40% of trauma deaths are due to excessive 
bleeding and occur in the first few hours after injury1,2. Severely injured patients that 
do survive the initial insult often develop persistent organ dysfunction associated with 
poor outcome1,3. Multiple organ dysfunction syndrome (MODS) is considered the 
leading cause of death and of poor-quality life after severe trauma3. The resuscitation 
after severe hemorrhage improves tissue perfusion, but also aggravates injury and 
triggers a systemic inflammatory response, both of which contribute to the 
development of MODS4,5. Although the precise mechanism responsible for MODS 
remains to be elucidated, inflammation plays a key role, and the increased release of 
inflammatory cytokines and nitric oxide (NO) importantly contribute to the 
pathophysiology of HS6,7. We have recently demonstrated that pharmacologic 
interventions which either reduce organ injury or increase the resistance of target 
organs against injury attenuate the MODS associated with HS8–11.  
Resolution of inflammation is a physiological active process, which is highly 
coordinated and regulated by several endogenous mediators of protein and lipid 
nature. As such, specialized pro-resolving mediators (SPMs), including lipoxins, 
protectins, maresins and resolvins, do not completely inhibit the inflammatory 
responses, but reprogram the immune response to accelerate resolution of 
inflammation and repair12–14. SPMs exhibit protective roles in several inflammatory 
conditions, including arthritis15,16, sepsis17,18, burn injury19, uveitis20 and edema21.  
Resolvin D1 (RvD1), a bioactive lipid mediator synthesised from docosahexaenoic 
acid, is member of the resolvin family that mediates resolution of inflammation22,23. 
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RvD1 reduces the inflammation and lung injury caused by lipopolysaccharide24, it 
reduces the inflammation in endometriosis25, and improves survival in experimental 
sepsis26. However, therapeutic approaches that mimic or amplify these endogenous 
efforts to resolve inflammation and to initiate repair have not yet been investigated in 
trauma-hemorrhage. Thus, the aim of the present study is to evaluate the changes in 
the plasma levels of RvD1 in patients with severe trauma. Having found that trauma 
and hemorrhagic shock (HS) leads to a significant fall in the plasma levels of RvD1, 
we have then used a reverse-translational approach aimed at investigating the 
potential beneficial effects of synthetic RvD1 in a rat model of HS and MODS. 
METHODS 
Use of Human Subjects—Ethic Statement 
Healthy Volunteers: Volunteers gave written consent in accordance with a Queen Mary 
Research Ethics Committee (QMREC 2014:61) and the Helsinki declaration. Venous 
peripheral blood was collected at indicated intervals from fasting volunteers (n=8) that 
declared not taking NSAIDS for at least 14 days, caffeine and alcohol for at least 24h 
and fatty fish for 48h.  
Trauma Patients: Patients recruited into the Activation of Coagulation and 
Inflammation and Trauma (ACITII) study, a platform prospective observational study 
at an urban major trauma centre, were eligible for inclusion. The National Health 
Service (NHS) Research Ethics Committee (REC) provided ethical approval for this 
study (REC reference 07/Q0603/29). Informed consent for participation was obtained 
from the patient or their next of kin. All adult patients meeting criteria for trauma team 
activation were screened for inclusion. Exclusion criteria consisted of presentation 
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more than two hours after injury, administration of more than 2000 ml crystalloid prior 
to blood sampling, major burns and known bleeding diathesis or immunocompromise.  
Patient Selection: We selected a subset of critically injured patients from the ACITII 
cohort for inclusion into this study based on their injury profile and clinical course. 
Patients with an injury severity score (ISS) of ≥25 resulting from blunt force trauma 
were included (n=27). We excluded patients with severe traumatic brain injury 
(abbreviated injury score >3) and those who died within 48 hours of admission, to 
eliminate the confounding effects of severe head injury on the immune response and 
to focus on patients at risk of MODS.  
Data collection and Blood Sampling: Blood samples were collected immediately on 
arrival in the emergency department and within two hours of injury. Demographic data, 
admission physiology, mechanism of injury and blood product utilisation were collected 
prospectively on admission to hospital by a trained research fellow. HS was defined as 
a base deficit of >6mmol/L on arterial blood gas analysis at the time of sampling for 
RvD1 measurement, as previously described27,28. All patients were followed up daily 
over the first 28 days unless death or hospital discharge occurred sooner. Scores were 
calculated on each day of critical care unit stay. MODS was defined as a sequential 
organ failure assessment (SOFA) score of ≥5 occurring on two or more consecutive 
days, excluding the first 48h of admission, as previously described29–31. Additional 
outcome variables included ventilator and vasopressor utilisation, critical care and 
hospital length of stay, and 28-day mortality. 
RvD1 measurement using targeted liquid chromatography tandem mass spectrometry 
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Peripheral blood from healthy volunteers and patients was drawn into vacutainers 
containing 3.2% sodium citrate (Becton, Dickinson and company, Plymouth, UK) and 
centrifuged at 1500 x g for 10 minutes at room temperature. The plasma fraction was 
isolated and centrifuged again using the same settings before immediate storage at -
80°C. All samples were extracted using solid-phase extraction columns as in32,33. Prior 
to sample extraction, deuterated labelled RvD2 (500 pg per sample) was added to 
facilitate quantification in 4 volumes of cold methanol. Samples were kept at -20°C for 
a minimum of 45 min to allow protein precipitation. Supernatants were subjected to 
solid phase extraction, methyl formate fraction collected, brought to dryness and 
suspended in phase (methanol/water, 1:1, vol/vol) for injection on a Shimadzu LC-
20AD HPLC and a Shimadzu SIL-20AC autoinjector, paired with a QTrap 6500 plus 
(Sciex). An Agilent Poroshell 120 EC-C18 column (100 mm x 4.6 mm x 2.7 μm) was 
kept at 50°C and mediators eluted using a mobile phase consisting of methanol-water-
acetic acid of 20:80:0.01 (vol/vol/vol) that was ramped to 50:50:0.01 (vol/vol/vol) over 
0.5 min and then to 80:20:0.01 (vol/vol/vol) from 2 min to 11 min, maintained till 14.5 
min and then rapidly ramped to 98:2:0.01 (vol/vol/vol) for the next 0.1 min. This was 
subsequently maintained at 98:2:0.01 (vol/vol/vol) for 5.4 min, and the flow rate was 
maintained at 0.5 ml/min. QTrap-6500+ was operated using a multiple reaction 
monitoring method using ion pairs 375 > 141 and 375 > 215 as in32,33. RvD1 was 
identified using established criteria including matching retention time to synthetic and 
authentic materials and at least 6 diagnostic ions32,33. Calibration curves were obtained 
using synthetic compound mixtures at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 
200 pg that gave linear calibration curves with an r2 values of 0.98–0.99. 
Use of Experimental Animals—Ethic Statement 
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All animal procedures were approved by the Animal Welfare Ethics Review Board 
(AWERB) of Queen Mary University of London (PCF29685) in accordance with Home 
Office guidance on Operation of Animals (Scientific Procedures Act 1986) and Guide 
for Care and Use of Laboratory Animals of the National Research Council. Male Wistar 
rats (Charles River Ltd, UK) weighing 250 to 280 g receiving a standard diet and water 
ad libitum were used. 
Hemorrhagic Shock and Quantification of Organ Injury and Dysfunction  
HS was performed as previously described8,34. Briefly, rats were anesthetized with 
sodium thiopentone (120 mg/kg i.p. maintained using 10 mg/kg i.v.). Blood was 
withdrawn from the right carotid artery and collected with 2 IU/ml of heparin until the 
mean arterial pressure (MAP) reach 30±2 mmHg, which was maintained for 1.5 h. The 
shed blood was kept between 6-10oC. After 1.5h of initiation of hemorrhage, 
resuscitation was performed with the shed blood over a period of 5 min. An infusion of 
Ringer Lactate (1.5 mL/kg/hour; i.v.) was maintained throughout the experiment for a 
total of 4h. The last 3h urine was obtained for the estimation of creatinine clearance. 
Four hours after resuscitation, blood was collected from carotid artery for measurement 
of lactate (Accutrend Plus Meter, Roche Diagnostics, UK) and organ injury parameters 
(IDEXX Ltd, UK), and tissue samples were taken, placed on liquid nitrogen and stored 
at -80oC. Sham-rats were used as control and underwent identical surgical procedures, 
but without hemorrhage. 
Experimental Design  
Forty-two rats were randomly divided into the following groups (n=7 per group): 
sham+vehicle; sham+RvD1 (0.3 µg/kg); sham+RvD1 (1 µg/kg); HS+vehicle; HS+RvD1 
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(0.3 µg/kg) and HS+RvD1 (1 µg/kg). RvD1 was diluted in saline (vehicle) and rats were 
treated (i.v.) upon resuscitation.  
Immunohistochemistry  
Myeloperoxidase positive cells and ICAM-1 were detected through 
immunohistochemistry. Briefly, kidney and liver samples were obtained, fixed and 
processed to obtain 4µm sections. Sections were incubated with 0.03% H2O2 for 
inactivation of endogenous peroxidase (Dako EnVision+ System-HRP-DAB, K4010) 
and were blocked with 10% goat serum (15 min). The slides were then incubated with 
rabbit anti-ICAM-1 antibody (1:100; Cat# ab124760, Abcam, Cambridge, UK, 1 h, room 
temperature) or with rabbit anti-myeloperoxidase antibody (1:25; Cat# ab9535, Abcam, 
Cambridge, UK) for 1 h at 37°C. After washing with PBS, slides were incubated with 
labelled polymer-HRP antibody (Dako EnVision+ System-HRP-DAB, K4010), washed 
and incubated with DAB chromogen solution until a brown precipitate could be 
observed. A negative control was performed through the omission of primary antibody 
(data not shown). Reaction was stopped by immersing slides in water. Counter-
staining was performed with Harris haematoxylin. Images were acquired using 
NanoZoomer Digital Pathology Scanner (Hamamatsu Photonics K.K., Japan) and 
analysed using the NDP Viewer software. The relative quantification of ICAM-1 
immunostaining was achieved through densitometry analysis in 5 randomly selected 
fields (x400) per animal (5 per group) using NIH ImageJ 1.36 imaging software (NIH, 
Bethesda, MD, USA) and it is expressed as arbitrary units. The number of MPO 
positive cells was counted in 10 randomly selected fields (x400) in a double-blinded 
manner. 
Determinations of Cytokines 
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Serum and tissue cytokines TNF-α, IL-1β, IL-6 and IL-10 were determined using 
commercial immunoassay kits (R&D Systems, Minneapolis, MN). 
Western Blot Analysis 
Briefly, kidney and liver samples were homogenized in buffer and centrifuged (4000 
rpm, 5 min, 4oC). To obtain the cytosolic fraction, supernatants were centrifuged 
(14000 rpm, 4oC, 40 min). The pelleted nuclei were re-suspended in extraction buffer 
and centrifuged (14000 rpm, 20 min, 4oC). Protein content was determined on both 
nuclear and cytosolic extracts using bicinchoninic acid (BCA) protein assay (Thermo 
Fisher Scientific Inc, Rockford, IL). Semi-quantitative immunoblot analyses of the 
phosphorylation of IKK𝛼/𝛽, I𝜅B𝛼, nuclear translocation of p65 and expression of iNOS 
were carried out. Equal amounts of proteins were separated by SDS-PAGE and 
electrotransferred to PVDF membrane. After blocking (1h in 5% dry milk solution), 
membranes were incubated with primary antibodies (rabbit anti-NF-kB [1: 1000], rabbit 
anti-IKK𝛼/𝛽 [1:1000], rabbit anti-Ser176/180 IKK𝛼/𝛽 [1:5000], mouse anti-I𝜅B𝛼 [1:1000], 
mouse anti-Ser32/36 I𝜅B𝛼 [1:1000], rabbit anti-iNOS [1:1000]) followed by incubation 
with appropriated HRP-conjugated secondary antibodies. Proteins were detected with 
ECL detection system and quantified by densitometry using analytic software 
(Quantity-One, Bio-Rad, Hercules, CA, USA). Results were normalized with respect to 
densitometric value of tubulin for cytosolic proteins or histone H3 for nuclear proteins. 
Materials 
Unless otherwise stated, all compounds were from Sigma-Aldrich Company Ltd 
(Poole, Dorset, U.K.). Ringer’s Lactate was from Baxter Healthcare Ltd.; sodium 
thiopentone (Thiovet©) from Link Pharmaceuticals (Horsham, UK). The BCA protein 
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assay kit and SuperBlock blocking buffer were from ThermoFisher Scientific Inc. 
(Rockford, USA).  
Statistics  
All figures are expressed as box-and-whisker format showing medians, inter-quartile 
range and full range. The distribution of the data was verified by Shapiro-Wilk normality 
test, and the homogeneity of variances by Bartlett test. When necessary, values were 
transformed into logarithmic values to achieve normality and homogeneity of 
variances. Data were assessed by one-way ANOVA followed by Newman-Keuls post-
hoc test. Data that were not normally distributed were analysed with Kruskal-Wallis 
followed by Dunn’s test. Clinical samples were analysed by Mann Whitney test. A p-
value of less than 0.05 was considered significant. Statistical analysis was carried out 
using GraphPad Prism 5.03 (GraphPad Software, USA). 
RESULTS 
Resolvin D1 is significantly Reduced in Plasma from Trauma Patients who Develop 
Organ Dysfunction.  
Plasma was collected from healthy volunteers (n=8), severely injured trauma patients 
(n=12) and trauma + HS patients (n=15) and the concentrations of RvD1 were 
determined using LC-MS/MS. The median age and sex distribution of the three groups 
was similar. Trauma patients were critically injured [median ISS 38 (IQR 33-44)] but 
received minimal volumes of crystalloid [median 0mL (IQR 0-300)] prior to blood 
sampling. Detailed patient demographics and injury characteristics are reported in 
supplemental table 1 (see Table, Supplemental Digital Content 1). When compared to 
healthy volunteers (HV) and trauma patients (T), patients with concomitant trauma and 
 14 
HS (T+HS) had significantly lower plasma levels of RvD1 (HV: 0.76±0.25; T: 0.62±0.20 
and T+HS 0.17±0.08, p=0.02; Fig. 1). 
Resolvin D1 Reduces Multiple Organ Failure Induced by HS in Rats 
Having demonstrated that patients with T+HS bear marked reduction in RvD1 plasma 
levels, we next explored whether pharmacological intervention with synthetic RvD1 
attenuates the MODS associated with HS in rats. 
Rats subjected to HS developed renal dysfunction as observed by an increase in 
serum creatinine (Fig. 2A) and a decrease in creatinine clearance (Fig. 2B). HS-rats 
also developed significant increases in serum AST (Fig. 2C) and ALT (Fig. 2D), 
indicating the development of liver injury; increases of creatine kinase (CK; Fig. 2E) 
and lactate (Fig. 2F) indicating the development of muscular injury and tissue/organ 
ischemia, respectively. Administration of RvD1 upon resuscitation (after a period of 
prolonged hemorrhage) resulted in a dose-dependent reduction in the organ 
injury/dysfunction. No differences in heart rate and urine output were observed among 
any of the groups studied (see Supplemental Table 2, Supplemental Digital Content 
2). As the higher dose of 1 µg/kg of RvD1 showed the largest beneficial effect, we used 
kidney and liver biopsies of HS-animals treated with either vehicle or 1µg/kg of RvD1 
to investigate the mechanism(s) of the observed beneficial effects of RvD1 in 
experimental HS. Administration of RvD1 to sham-animals had no significant effect on 
any of the parameters evaluated (data not shown). 
Resolvin D1 Reduces MPO Positive Cells and ICAM-1 Expression in Liver and Kidney 
When compared to sections of both kidneys and livers of sham rats, those of HS-rats 
treated with vehicle showed a significant increase in cells expressing MPO (a specific 
marker of local neutrophil accumulation) and a significant upregulation of the adhesion 
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molecule ICAM-1, which is the endothelial ligand for the neutrophil receptor 
CD11b/CD18, in both kidney (Figs. 3A, B, E and Figs. 4A, B, E) and liver (Figs. 3F, G, 
J and Figs. 4F, G, J). The treatment of HS-rats with RvD1 significantly reduced the 
markers of neutrophil infiltration (Figs. 3D, E, I, J and Figs. 4D, E, I, J). 
Resolvin D1 Attenuates the Activation of the NF-B Pathway 
When compared to sham animals, rats subjected to HS developed a significant 
increase in the phosphorylation of IKKαβ (Figs. 5A and D), IκBα (Figs. 5B and E) 
resulting in a nuclear translocation of the p65 NF-κB subunit (Figs. 5C, F) in the kidney 
(Figs. 5A-C) and liver (Figs. 5D-F) suggesting significant activation of the NF-κB 
pathway in both organs. Treatment of the HS-rats with RvD1 on resuscitation 
significantly attenuated the phosphorylation of IKKαβ, IκBα and the translocation of the 
p65 NF-κB subunit to the nucleus in both organs (Fig. 5). 
Resolvin D1 Reduces Pro-inflammatory proteins Induced by HS 
As RvD1 decreased the nuclear translocation of p65 NF-κB, we investigated the effects 
of RvD1 on the expression of NF-κB-dependent pro-inflammatory proteins. Kidney 
biopsies from HS rats exhibited a significant increase in iNOS expression (Fig. 6A) and 
in the concentrations of the pro-inflammatory cytokines TNF-α (Fig. 7E), IL-1β (Fig. 7F) 
and IL-6 (Fig. 7G). In the liver, only iNOS expression (Fig. 6B) and IL-1 β (Fig. 1J) 
levels were significantly higher than in the livers obtained from sham-animals. When 
compared to sham animals, HS also resulted in a significant increase in the pro-
inflammatory cytokines TNF-α (Fig. 7A), IL-1β (Fig. 7B) and IL-6 (Fig. 7C), and in the 
anti-inflammatory cytokine IL-10 (Fig. 7D) in the blood. Treatment of HS-rats with RvD1 
significantly attenuated the observed increases in tissue/blood cytokines and iNOS 
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expression caused by HS (Fig. 6 and Fig. 7). It should be noted that treatment of sham-
rats with RvD1 had no significant effect on any of the parameters measured.  
DISCUSSION 
We report here for the first time that trauma patients who experienced significant 
hemorrhage had a significant reduction in the plasma levels of the pro-resolution 
mediator RvD1. As there is good evidence that RvD1 is a powerful, pro-resolving 
mediator in man12–14,35, we postulated that a reduction in endogenous levels of RvD1 
could contribute to excessive systemic inflammation and organ injury/dysfunction. To 
investigate this hypothesis, we have used a reverse-translational approach (from 
humans to rodents) in which we have investigated the potential beneficial effects of 
synthetic RvD1 in a well-established rat model of HS, previously reported in this 
journal8,11. Most notably, we report here that administration of RvD1 on resuscitation 
(following a 90 min period of severe hemorrhage) attenuated HS-induced systemic 
inflammation and organ injury/dysfunction (renal dysfunction, liver injury, 
skeletomuscular injury and tissue hypoxia).  
What, then, are the mechanisms by which RvD1 reduces both systemic inflammation 
and organ injury/dysfunction in experimental HS? There is now very good evidence 
that RvD1 has potent anti-inflammatory effects: specifically, RvD1 reduces 
polymorphonuclear leukocyte infiltration36, inhibits activation of the NF-κB pathway24,37 
and reduces the formation of pro-inflammatory cytokines38. However, so far, none of 
these beneficial effects of RvD1 have been demonstrated in settings of HS. Here we 
demonstrated, that the MODS-related activation of NF-κB cascade (measured as 
IKKα/β phosphorylation, IκBα phosphorylation and nuclear translocation of p65) in 
kidney and liver, and the following enhanced formation of many NF-κB-dependent 
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proteins including TNF-α, IL-1β, IL-6, IL-10 (kidney, liver, serum) and iNOS (in kidney, 
liver), are strongly inhibited by RvD1 administration. Taken together, these findings not 
only further confirm the key role of NF-κB activation in the pathophysiology of the 
MODS in HS, but, most notably, form the basis for our current working hypothesis that 
the observed reduction in MODS afforded by RvD1 is secondary to inhibition of NF-
κB. We have not investigated the detailed mechanism(s) by which RvD1 inhibits the 
activation of NF-κB, thus we cannot rule out potential indirect effects due to RvD1 
interference with other inflammatory cascades. Nevertheless, the pro-resolving effects 
of RvD1 are known to be secondary to interactions with the receptors ALX/FPR2 and/or 
GPR32, whose activation has been demonstrated to directly downregulate NF-κB p65 
nuclear translocation39–41. Indeed, there is evidence in both human endothelial and 
epithelial cells42,43 which supports the view that activation of either ALX/FPR2 or 
GPR32 by RvD1 results in inhibition of nuclear translocation of p65, whereas the pre-
treatment of these cells with specific ALX/FPR2 antagonists or a GPR32-neutralizing 
Ab abolished the inhibition of NF-κB afforded by RvD1 in these cells in vitro. Thus, we 
speculate that the inhibition of NF-κB afforded in our study by RvD1 administration is 
also secondary to activation of ALX/ FPR2 and/or GPR32. 
There is good evidence that excessive formation of the proinflammatory cytokines 
TNF-α, IL-1β and IL-6 contribute to both development of MODS and mortality in 
HS34,44–46. We report here that administration of RvD1 on resuscitation attenuated the 
HS-induced formation of these proinflammatory cytokines. RvD1 treatment has also 
attenuated the increase of the anti-inflammatory cytokine IL-10 caused by HS in rats, 
and reduction in IL-10 improves outcome in experimental HS9. In patients with trauma-
HS, increases in IL-10 are associated with immunosupression and delayed clinical 
recovery47,48, Thus, the reduction of IL-10 may have contributed to the beneficial 
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effects of RvD1 in HS. Our result corroborate previous studies reporting that RvD1 
reduces IL-10 formation in septic shock49. 
The formation of proinflammatory cytokines including TNF-α and IL-1β drives the 
expression of iNOS in many disease states. There is good evidence that the excessive 
formation of nitric oxide by iNOS contributes to the development of MODS in rodents 
with HS and that inhibition of iNOS activity reduces MODS6–9. We report here that 
RvD1 abolishes the expression of iNOS caused by HS in the kidney and attenuates 
the expression caused by HS in the liver. Thus, we propose that prevention of the 
expression of iNOS importantly contributes to the beneficial effects of RvD1. 
Neutrophils play a key role in the MODS associated with HS. Neutrophils bind to ICAM-
1 expressed on endothelial cells and drives the recruitment of neutrophils into tissues; 
these neutrophils cause direct local cytotoxic cellular effects through the release of 
mediators such as reactive oxygen species, nitric oxide, cytokines and MPO45. We 
report here that the reduction in MODS afforded by RvD1 is associated with a reduced 
recruitment of neutrophils to target organs (kidney and liver) and this was due to 
reduced expression of ICAM-1 in these tissues. These protective actions of RvD1 are 
also in line with findings made during ischemia-reperfusion injury as well as with 
primary human leukocytes where RvD1 was found to regulate neutrophil recruitment 
and protect against neutrophil mediated organ injury40,50. 
Limitations of the study: Although the improvement of organ dysfunction by RvD1 is an 
interesting finding, we have evaluated the animals in a short follow-up and in a single 
time-point (4 h after surgery). We have also not investigated the effects of RvD1 on 
other important organs involved in the MODS associated with HS including the lungs 
and the heart or in mortality rate. Thus, the results must be cautiously interpreted and 
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carefully extrapolated to a clinical situation. Further studies in in vivo HS survival 
protocols and in larger cohorts of trauma patients are required to assess the 
relationships between RvD1 and clinical outcomes in humans, including measurement 
of RvD1 kinetics over time. 
In summary, this paper shows that the development of MODS in patients with severe 
trauma/HS is associated with low plasma levels of RvD1. This finding formed the basis 
for our hypothesis that a restoration of higher plasma levels of RvD1 may reduce the 
MODS associated with trauma/HS. Indeed, administration of RvD1 on resuscitation 
(after a 90-min period of severe hemorrhage) reduced the organ dysfunction and injury 
as well as the local and systemic inflammation associated with HS. We propose that 
these beneficial effects of RvD1 are secondary to inhibition of the activation of NF-κB 
resulting in reduced formation of pro-inflammatory cytokines, NO from iNOS and 
neutrophil recruitment into target tissues (secondary to expression of ICAM-1). Thus, 
we believe that the reduction of MODS by RvD1 in the rodent model used here may 
be useful in the development of a preclinical dossier with the ultimate aim to evaluate 
RvD1 in patients with trauma-hemorrhage. 
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FIGURE LEGENDS 
Fig. 1: RvD1 is significantly reduced in plasma from trauma / hemorrhagic shock 
patients. Plasma was collected from healthy volunteers (n = 8), trauma patients (n=12) 
and trauma+HS patients (n=15) and the concentrations of RvD1 were determined 
using LC-MS/MS based lipid mediator profiling. (A) Multiple reaction monitoring 
chromatogram (B) MS-MS spectrum used for the identification of RvD1. (C) Plasma 
RvD1 concentrations. Data are presented as box and whiskers, showing medians, 
inter-quartile range and full range. * p<0.05 using Kruskal-Wallis followed by Dunn’s 
test. 
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Fig. 2. RvD1 attenuates the organ injury and dysfunction induced by HS. (A) 
serum creatinine, (B) creatinine clearance, (C) serum aspartate aminotransferase 
(AST), (D) serum alanine aminotransferase (ALT), (E) serum creatine kinase (CK) and 
(F) lactate of HS-rats treated with vehicle or RvD1 (0.3 or 1.0 µg/kg) on resuscitation 
are shown. Sham rats were treated with vehicle or RvD1 (0.3 or 1.0 µg/kg). Data are 
presented as box and whiskers, showing medians, inter-quartile range and full range 
(n = 7 animals per group). Statistical analysis was performed using one-way ANOVA 
followed by Newman-Keuls post hoc test. *p < 0.05 versus sham + vehicle and #p < 
0.05 versus HS + vehicle. 
Fig. 3. RvD1 reduces the increased number of MPO positive cells in kidney and 
liver tissue induced by HS. MPO positive cells recruitment in kidney (A-E) and liver 
(F-J) of sham (A, C, F, H) and HS-rats (B, D, G, I) treated with vehicle (A, B, F, G) or 
RvD1 (1.0 µg/kg; C, D, H, I) on resuscitation were determined by 
immunohistochemistry. Data are presented as box and whiskers, showing medians, 
inter-quartile range and full range (n = 5 animals per group; E, J). Statistical analysis 
was performed using one-way ANOVA followed by Newman-Keuls post hoc test. *p < 
0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
Fig. 4. RvD1 attenuates the expression of ICAM-1 in kidney and liver tissue 
induced by HS. ICAM-1 expression in kidney (A-E) and liver (F-J) of sham (A, C, F, 
H) and HS-rats (B, D, G, I) treated with vehicle (A, B, F, G) or RvD1 (1.0 µg/kg; C, D, 
H, I) on resuscitation are shown. Data are presented as box and whiskers, showing 
medians, inter-quartile range and full range (n = 5 animals per group; E, J). Statistical 
analysis was performed using Kruskal-Wallis test followed by Dunn’s post hoc test. *p 
< 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
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Fig. 5. RvD1 attenuates the activation of NF-κB pathway induced by HS. The 
phosphorylation of IKK on Ser176/180 (A and D), IκBα on Ser32/36 (B and E) and the 
nuclear translocation of the p65 NF-κB subunit (C and F) in the kidney (A-C) and liver 
(D-F) of sham and HS rats treated with RvD1 were determined by western blotting. 
Protein expression was measured as relative optical density (O.D.), corrected for the 
corresponding β-actin or Histone contents and normalized using the related sham 
band. Data are presented as box and whiskers, showing medians, inter-quartile range 
and full range (n = 7 animals per group). Statistical analysis was performed using 
Kruskal-Wallis test followed by Dunn’s post hoc test. *p < 0.05 versus sham + vehicle 
and #p < 0.05 versus HS + vehicle. 
Fig. 6. RvD1 attenuates iNOS expression in liver and kidney tissue induced by 
HS. The iNOS expression in the kidney (A) and liver (B) of sham and HS rats treated 
with vehicle or RvD1 (1.0 µg/kg) on resuscitation were determined by western blotting. 
Protein expression was measured as relative optical density (O.D.), corrected for the 
corresponding tubulin content and normalized using the related sham band. Data are 
presented as box and whiskers, showing medians, inter-quartile range and full range 
(n = 7 animals per group). Statistical analysis was performed using Kruskal-Wallis test 
followed by Dunn’s post hoc test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus 
HS + vehicle. 
Fig. 7. RvD1 attenuates cytokines production induced by HS. The serum (A-D), 
kidney (E-H) and liver (I-L) amounts of TNF-α (A, E, I), IL-1β (B, F, J), IL-6 (C, G, K) 
and IL-10 (D, H, L) were determined by ELISA in sham and HS-rats treated with vehicle 
or RvD1 (1.0 µg/kg) on resuscitation. Data are presented as box and whiskers, 
showing medians, inter-quartile range and full range (n = 7 animals per group). 
Statistical analysis was performed using one-way ANOVA followed by Newman-Keuls 
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post hoc test. *p < 0.05 versus sham + vehicle and #p < 0.05 versus HS + vehicle. 
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